Diagnosing COVID-19-associated pulmonary aspergillosis
Open accessAbstract
There is increasing concern that patients with coronavirus disease 2019 (COVID-19) might be at risk of developing invasive pulmonary aspergillosis co-infection.1 In a cohort of 221 patients with COVID-19 in China, fungal infections were diagnosed in seven individuals, all of whom were admitted to the intensive care unit (ICU).2 However, causative fungal pathogens were not identified.2 Given that in China, galactomannan testing is rarely available,3 the real burden of invasive pulmonary aspergillosis in patients with COVID-19 requiring ICU admission is probably underestimated.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Serum galactomannan detection for diagnosis of aspergillosis in COVID-19 patients is less sensitive than in influenza patients for currently unknown reasons.
“Serum galactomannan detection for diagnosis of aspergillosis in COVID-19 patients is less sensitive than in influenza patients for currently unknown reasons”
From Co-infections in people with COVID-19: a systematic review and meta-analysis. (2020) · cites this paper as [63]
Galactomannan testing is not validated for upper respiratory tract specimens.
“and galactomannan testing is not validated for upper respiratory tract specimens.63”
From Co-infections in people with COVID-19: a systematic review and meta-analysis. (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750 · see citing works
Schauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommers, D., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30274-1 · Cited by 886 · see citing works
Self-citationClinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China
Zhang, G., Hu, C., Luo, L., Fang, F., Chen, Y., Li, J., Peng, Z., & Pan, H. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104364 · Cited by 691 · see citing works
COVID-19 Associated Pulmonary Aspergillosis
Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., et al. (2020) · Mycoses · doi:10.1111/myc.13096 · Cited by 547 · see citing works
Self-citationGalactomannan in Bronchoalveolar Lavage Fluid
Meersseman, W., Lagrou, K., Maertens, J., Wilmer, A., Hermans, G., Vanderschueren, S., Spriet, I., Verbeken, E., & Van Wijngaerden, E. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200704-606oc · Cited by 496 · see citing works
High Prevalence of Putative Invasive Pulmonary Aspergillosis in Critically Ill COVID-19 Patients
Alanio, A., Dellière, S., Fodil, S., Bretagne, S., & Mégarbane, B. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30237-x · Cited by 459 · see citing works
Invasive fungal diseases during COVID-19: We should be prepared
Gangneux, J., Bougnoux, M., Dannaoui, É., Cornet, M., & Zahar, J. (2020) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2020.100971 · Cited by 346 · see citing works
Self-citationWahidi, M. M., Lamb, C., Murgu, S. D., Musani, A. I., Shojaee, S., Sachdeva, A., Maldonado, F., Mahmood, K., Kinsey, M., Sethi, S., et al. (2020) · Journal of Bronchology & Interventional Pulmonology · doi:10.1097/lbr.0000000000000681 · Cited by 234 · see citing works
Fatal Aspergillosis in a Patient with SARS Who Was Treated with Corticosteroids
Wang, H., Ding, Y., Li, X., Yang, L., Zhang, W., & Kang, W. (2003) · New England Journal of Medicine · doi:10.1056/nejm200307313490519 · Cited by 166 · see citing works
Henriet, S., Jans, J., Simonetti, E. R., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit103 · Cited by 39 · see citing works
High Prevalence of Putative Invasive Pulmonary Aspergillosis in Critically Ill COVID-19 Patients
Alanio, A., Dellière, S., Fodil, S., Bretagne, S., & Mégarbane, B. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3575581 · Cited by 27 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [9]Dewi IMW, Cunha C, Vanderbeke L, et al. Oseltamivir affects host defense against invasive pulmonary aspergillosis. European Conference on Clinical Microbiology and Infectious Diseases; Madrid; April 21–24, 2018. Abstract O1115.
Cited by
Sorted by citations
Co-infections in people with COVID-19: a systematic review and meta-analysis.
Lansbury, L., Lim, B., Baskaran, V., & Lim, W. S. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.046 · Cited by 1,619 · see citing works
Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection
Bao, L., Zhang, C., Dong, J., Zhao, L., Li, Y., & Sun, J. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01840 · Cited by 207 · see citing works
Jenks, J. D., Gangneux, J.-P., Schwartz, I. S., Alastruey-Izquierdo, A., Lagrou, K., Thompson III, G. R., Lass-Flörl, C., Hoenigl, M., & Investigators, E. C. O. M. M. (. C. (2020) · Journal of Fungi · doi:10.3390/jof6040216 · Cited by 44 · see citing works
Self-citation
- Authors
- Verweij, P. E., Gangneux, J.-P., Bassetti, M., Brüggemann, R. J. M., Cornely, O. A., Koehler, P., Lass-Flörl, C., van de Veerdonk, F. L., Chakrabarti, A., & Hoenigl, M.
- Affiliations
- Radboud University Nijmegen (NL)
- Inserm (FR)
- Ospedale Policlinico San Martino (IT)
- University of Cologne (DE)
- Post Graduate Institute of Medical Education and Research (IN)
- Medical University of Graz (AT)
- Corresponding author
- Verweij, Paul E
- ORCID
- Venue
- The Lancet Microbe
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 1
- Issue
- 2
- Pages
- e53-e55
- ISSN
- 2666-5247 (ISSN-L)
- PMC
- PMC7211496
- OpenAlex
- W3021335315
- Cited by
- 181
- References
- 11
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 21 · 2022: 33 · 2021: 50 · 2020: 56 · 2013: 1
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Update notices
- erratum (2020-07-01)
- Open access
- gold
- doi.org
- Licence
- Locations
- The Lancet Microbe (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Greater South Information System
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- COVID-19 pandemic, invasive pulmonary aspergillosis, fungal co-infection, diagnostic testing, galactomannan assay, intensive care unit patients, SARS-CoV-2
- MeSH terms
- COVID-19, Aspergillosis, Allergic Bronchopulmonary, Humans, Pulmonary Aspergillosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
